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Background: Thyroid hormone inﬂuences gene expression in virtually all vertebrates. Its action is initiated by
the activation of T4 to T3, an outer ring deiodination reaction that is catalyzed by the type 1 or the type 2
iodothyronine selenodeiodinases (D1 or D2). Inactivation of T4 and T3 occurs via inner ring deiodination cat-
alyzed by the type 3 iodothyronine selenodeiodinases (D3). The T4 concentration is generally quite stable in
human plasma, with T3 levels also remaining constant. Deiodinase actions are tightly regulated in both pre-
and post-natal life when they are required to make local adjustments of intracellular T3 concentrations in a
precise spatio- and temporal manner. Although all the signals governing the dynamic expression of
deiodinases in speciﬁc cell types are not known, many important regulatory factors have been deciphered.
Scope of review: This review provides striking examples from the recent literature illustrating how the ex-
pression of D2 and D3 is ﬁnely tuned during maturation of different organs, and how their action play a crit-
ical role in different settings to control intracellular T3 availability.
Major conclusions: Emerging evidence indicates that in various cell contexts, D2 and D3 are expressed in a dy-
namic balance, in which the expression of one enzyme is coordinately regulated with that of the other to
tightly control intracellular T3 levels commensurate with cell requirements at that time.
General signiﬁcance: Deiodinases control TH action in a precise spatio-temporal fashion thereby providing a
novel mechanism for the local paracrine and autocrine regulation of TH action. This remarkable tissue-
speciﬁc regulation of intracellular thyroid status remains hidden due to the maintenance of constant circulat-
ing TH concentrations by the hypothalamic–pituitary–thyroid axis. This article is part of a Special Issue
entitled Thyroid hormone signalling.© 2012 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Thyroid hormone (TH) is important for the normal development
of many tissues, and for the regulation of their function throughout
life. Thyroid hormone can enter the cells via membrane transporters,
and, while diffusing from the plasma membrane to the nucleus, its
concentration can be modiﬁed by the action of the deiodinases.
Many genes have been identiﬁed whose expression is under the pos-
itive or negative control of TH. Although TH-dependent processes are
coordinated, they are not necessarily synchronized between tissues,otentials; D1, Type 1 seleno
leno deiodinase; Mpc, muscle
one; TR, thyroid hormone re-
d hormone signalling.
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-ND license.and the proper function of the organism requires tissue-speciﬁc
changes in TH action. These varying local requirements cannot be
governed by global mechanisms such as an alteration of thyroid
gland function or by modulation of hormone concentrations at plas-
ma level, but instead require tissue-speciﬁc regulation. The tissue-
speciﬁc-expression of deiodinases is gaining increased recognition
in the ﬁeld of TH action as a potent mechanism by which T3 levels
can be controlled at the local level with D2 converting the
prohormone T4 to the active hormone T3, while D3 converts T4 and
T3 to inactive metabolites [1].
The iodothyronine deiodinase family of selenoproteins consists of
three enzymes (D1, 2, and 3; or DIO1, 2, and 3) differentially
expressed in several adult and fetal tissues.
All deiodinases are membrane-anchored proteins of 29–33 kDa
that share substantial sequence homology, catalytic properties and
contain selenocysteine (Sec) as the key residue within their catalytic
centers. The unique feature of selenoproteins in general and
deiodinases lies in the recoding of the UGA codon from a stop
codon to Sec-insertion codon by the presence of the SECIS element
in the 3′ UTR of the respective mRNAs. Iodinated contrast agents
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pylthiouracil is a relatively speciﬁc inhibitor for D1.
D1 is primarily expressed in the liver, the kidney and the thyroid.
It is able to deiodinate both the inner and the outer ring of T4, and is
essential to provide T3 for the circulation as well as serving as a scav-
enger enzyme for iodide in peripheral tissues [2].
D2 is localized in the endoplasmic reticulum and its action is
directed almost exclusively at the efﬁcient conversion of the
prohormone T4 to the active T3 by 5′-deiodination. It is negatively
regulated by thyroid hormone both pre- and posttranscriptionally
[3]. Thus, in hypothyroidism, D2 activity is markedly up-regulated
[4,5], and this increases the proportion of T3 formed locally in
D2-expressing tissues.
D3 is localized in the plasma membrane and is considered as the
major thyroid hormone-inactivating enzyme. It inactivates T4 and
T3 by converting them to the inactive iodothyronines (rT3 and 3,3′-
diiodothyronine, T2). D3 expression is decreased in hypothyroidism
and increased in the thyrotoxic state [2].
Here we provide examples illustrating the importance of the
deiodinases in the tissue-speciﬁc modulation of TH action that high-
lights the importance of thyroid hormone receptor ligand availability
in controlling maturation and cellular proliferation/differentiation
within different organs.
2. Deiodinases and the proliferation/differentiation balance
2.1. Deiodinases in skin
Skin, a major target for TH, is a large tissue where the intracellular
TH concentration is modulated by a balance between the activating
(D2) and inactivating (D3) selenodeiodinases. In skin, TH exerts
profound effects on fetal epidermal differentiation, barrier formation,
hair growth, sebum production, wound healing, epidermal oxygen
consumption, keratinocyte proliferation, and keratin gene expres-
sion [6–12]. As a result, thyroid dysfunction is correlated with alter-
ations in skin architecture and homeostasis [10,13] and changes in
circulating TH levels, particularly hypothyroidism, are often associated
with an edema-like-associated skin condition caused by increased gly-
cosaminoglycan deposition. Thyroid hormone receptor expression has
been found in different skin cell types, including keratinocytes, dermal
ﬁbroblasts, and sebaceous gland cells, and both D2 and D3 activities
have also been detected in human skin [14–17].
The effects of TH on keratinocyte proliferation and epidermal dif-
ferentiation are controversial, with divergent results [8]. Safer's group
has found that systemic and topical TH administration cause diverg-
ing effects on keratinocyte proliferation. While topical T3 stimulates
epidermal proliferation, hair growth and dermal thickening [18–20],
systemic thyrotoxicosis leads to thinning of skin, hair and collagen
loss [19,21]. The authors postulate that the different effects exerted
by topical versus systemic TH treatment on epidermal cell can be
explained by the T3-induced production of inhibitory factor(s) from
ﬁbroblasts with systemic T3-treatment.
In keeping with the ability to modulate growth and differentia-
tion, it is not surprising that TH might play a critical role in skin
tumorigenesis. TH treatment decreases the proliferation and cyclin
D1 expression in transformed keratinocytes in a dose and time-
dependent fashion [17]. In human and mouse basal cell carcinoma
(BCC), a keratinocyte-derived tumor that is the most commonly diag-
nosed human cancer, D3 is overexpressed and lies downstream of the
Sonic hedgehog (Shh) pathway [17]. Inappropriate activation of the
Shh–Gli signaling pathway occurs in up to 25% of human tumors,
and constitutively activated Shh in skin is the causal lesion and the
molecular hallmark of BCCs. In primary keratinocytes, as well as in
BCCs, Shh increases the expression of D3, acting via a conserved
Gli2 binding site on the Dio3 promoter [17]. Indeed, D3, the main
TH inactivating enzyme, is often referred to as an oncofetal proteinbecause its expression is very low in most adult tissues, but increased
in several human cancers and in human solid tumors. Inhibition of D3
expression diminishes cell proliferation by increasing nuclear T3 ac-
tion [17]. The Shh-mediated induction of D3 strongly suggests the ex-
istence of a novel cross-talk in which Shh induces local attenuation of
the TH signal, thus contributing to enhanced cell proliferation. Hh
control of TH signaling has also been found to play an important
role in the tibial growth plate, in which Indian Hedgehog induces
the expression of WSB-1 and thus targets D2 for proteasomal degra-
dation — a process that results in a local decrease in T3 levels and in-
creased chondrocyte proliferation [22]. Thus, the functional interplay
between the Hh pathways and TH metabolism identiﬁed in the tibial
growth plate and BCCs [17,22] may have a much broader signiﬁcance
and relevance to other tissues or pathological conditions.
2.2. Deiodinases are critical for the development of normal auditory
function
Hearing impairment has long been recognized as a clinical conse-
quence of congenital hypothyroidism or severe iodine deﬁciency, in
humans and various rodent models [23–25]. More recent studies in-
dicated that inactivation of the gene encoding the beta isoform of
the thyroid hormone receptor TRβ (Thrb) resulted in hearing deﬁ-
ciency [26,27], as demonstrated by defective auditory-evoked
brainstem potentials (ABR), thereby indicating that normal auditory
development required this isoform of the thyroid hormone receptor.
Impaired hearing has also been described in patients affected by the
syndrome of thyroid hormone resistance and bearing mutations in
the Thrb gene [28]. Studies in knockout mice models further indicate
that while the TRα1 isoform is not an absolute requirement for nor-
mal auditory development, there is a synergism between the α and
β thyroid receptor subtypes for both normal function and the ana-
tomical development of structures within the cochlea. Differential ef-
fects were further observed with TRβ versus TRα1 deletions, which
indicate that the two receptors also exert cell-speciﬁc effects [29].
Early studies in the rat showed that monodeiodination of T4 by a
propylthiouracil-insensitive deiodinase, D2, was responsible for ap-
proximately 80% of the T3 present in the cerebral cortex [30–32]. In
addition, the T3 and T4-inactivating D3 was also found to be highly
expressed, predominantly in neurons, and positively regulated by
T3 [33–35]. The D2 mRNA in the cortex was reported to be negatively
regulated by T4 and T3 at both transcriptional (T3) and post-
translational levels, which suggests that these two deiodinases act
in concert to facilitate T3 homeostasis in the central nervous system
structures [33–35]. A similar process has also been found to occur
during iodine deﬁciency [36].
The above observations have led to a series of studies to deﬁne the
role played by these two deiodinases in the development and func-
tion of the cochlea, and to determine how they correlate with the ex-
pression of the TH receptors and transporters. These studies have
revealed that the iodothyronine deiodinases play an essential role in
controlling cochlear development. The following discussion focuses
on the qualitative and quantitative aspects of D2 and D3 expression
during the development of this complex organ. The interested reader
is referred to the original articles referenced herein for details of the
structural basis underlying the disruption of auditory function when
the actions of these enzymes are blocked.
Initial studies determined that D2 activity in mouse cochlear tis-
sue increases abruptly starting at P4, peaks at P7 at levels about 10-
times the initial values, and returns to basal levels by P10–12
(Fig. 1). This occurs before the initiation of hearing, as monitored by
ABR. Of note, the peak of D2 activity precedes the peak of circulating
T4 and T3 in the neonatal mouse at P16. The increase in D2 activity is
accompanied by an approximately 4- to 5-fold increase in the T3 con-
tent of the cochlea, as well as a 3-fold increase in cochlear T4 concen-
trations. This results in a higher T3/T4 ratio in this tissue than in the
Fig. 1. Postnatal D2 enzymatic activity in the cochlea. D2 activity is high in the early
phases of postnatal cochlea maturation; it peaks at P7 and returns to basal levels by
P10. Interestingly, the high D2 expression precedes the rise in cochlear T3 and T4,
which indicates that local 5′ deiodination plays a critical role in the regulation of the
intracellular T3 concentration.
Figure modiﬁed from [37].
Fig. 2. TH transporter levels in cochlea. (A) The expression of Lat1, Mct8, Mct10, and
Oatp1C1 was evaluated in cochlea during embryonic development and early postnatal
phases. All transporters are upregulated during postnatal growth and their expression
parallels the expression of D2 mRNA (B) thereby providing the T4 substrate for
D2-mediated deiodination. Oatp, organic anion-transporting polypeptide, Mct,
monocarboxylate transporter, and Lat, L-type amino acid transporter.
Figure modiﬁed from [42].
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circulating thyroid hormones and an increase in outer ring mon-
odeiodination of T4 by D2 since D1 is not found in the cochlea. In ad-
dition, in situ hybridization studies indicated that the expression of
D2 was not in the sensory structures of the organ but predominantly
in the supporting connective tissue [37]. Furthermore, D2 expression
did not parallel that of either TRβ or TRα. These data suggested that
speciﬁc TH-independent signals in the connective tissue of the
cochlea were responsible for the marked increase in the local concen-
tration of T3 generated by D2.
The importance of D2 in this system was conﬁrmed by data
obtained in mice in which the Dio2 gene was inactivated [38]. Despite
the fact that the circulating T4 concentration in the D2KO mouse is
slightly increased and serum T3 concentrations are normal, impaired
ABR and anatomical abnormalities occurred in these animals. Studies
of the ABR of D2KO mice indicated that the absence of D2 resulted in
auditory dysfunction comparable to that found in hypothyroid mice.
This ﬁnding conﬁrmed that local cochlear T3 production plays a crit-
ical role in normal development. It was also found that a decrease in
D3 did not occur to compensate for the deﬁciency of cochlear T3 in
the absence of D2. The functional abnormality in D2KO hearing was
accompanied by delayed differentiation of the sensory epithelium
and of the tectorial membrane, a structure that is critical in cochlear
function. Interestingly, the impaired hearing was rescued by
supplementing maternal drinking water with high quantities of T3
by P10, but hearing did not completely normalize when T3 supple-
mentation was delayed until P16 or later. The improvement in
hearing with maternal T3 supplementation was matched by normal-
ization of cochlear anatomy in the D2KO mice, thus indicating that
the rescued function was due to a direct effect on the cochlea rather
than to normalization in the extra-cochlear neurological components
of the auditory system, which could also be dependent on D2. Serum
concentrations were 2- to 5-fold higher in offspring of nursing
mothers receiving a T3 supplement than in untreated D2KO mice,
conﬁrming that physiological concentrations of circulating T3 are in-
sufﬁcient to provide the amount of T3 required for normal cochleardevelopment. This observation is similar to ﬁndings obtained in the
pituitary and skeletal muscle [39–41]. The fact that auditory function
could be partly rescued by T3 treatment as late as P16 is thought to be
due to the relatively long time required for complete development of
hearing in the mouse, which extends beyond the spike in D2 activity
at P4–P8 (Fig. 1).
The increase in brain tissue T4 at P8 seen in the initial studies
suggested that there might be increases in thyroid hormone trans-
porters, which could provide additional T4 for T3 production. To ver-
ify this hypothesis, Sharlin et al. evaluated the expression of Lat1,
Mct8, Mct10, and Oatp1C1. Lat1 is a high-afﬁnity transporter of T3
and T4, Oatp1C1 transports T4, whileMct8 and 10 can transport either
iodothyronine but have higher afﬁnities for T3 [42]. There were min-
imal relative changes in the expression of all but the Oatp1C1 mRNA,
which increased 15-fold between E18 and P3 and about 80-fold by
P15 (Fig. 2). This compared with a change in Dio2 expression of
400- to 500-fold between E18 and P7 (Fig. 2). There was, in addition,
an anatomical overlap of Oatp1C1 and Dio2 expression in the
modiolus, osseous spiral lamina, and spiral ligament of the cochlea.
While the Oatp1C1 protein has been primarily identiﬁed in
microvessels, in the cochlea, this mRNA appeared to be localized to
ﬁbrocytes in close proximity to blood vessels. These results suggest
that the Oatp1C1 transporter is critical because it provides the T4 sub-
strate for D2. Mct8 was also detected in ﬁbrocytes, although its ex-
pression was not ampliﬁed during the developmental process.
Sharlin et al., also noted that the Oatp1C1 gene is localized within a
large segment of chromosome 12, which contains the Dfnb62 deaf-
ness locus — a ﬁnding consistent with a potential causal relationship
between a defect in T4 uptake in D2-expressing tissues and impaired
hearing [42].
Since it is well established that D2 and D3 expression respond in
opposite ways to changes in thyroid status or to morphogenic signals
such as Sonic hedgehog, the authors also evaluated the expression of
D3 in cochlear structures [43]. Interestingly, levels of D3 mRNA were
high in the cochlea beginning at E13, and remained constant until
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D2 activity. Strikingly, in the D3KO mouse, there was severe impair-
ment of hearing as evidenced by the ABR, and immunohistochemical
studies indicated that there was premature differentiation of cochlear
structures [43]. Mice with a combined elimination of Thrb and Dio3
did not develop the premature maturation characteristic of the
D3KO animals, which indicates that this event was due to the actions
of T3. Further testing to determine whether T3 toxicity per se could
replicate the effects of local D3 deﬁciency showed that when T3 was
administered between P0 and P3, there was a dose-dependent im-
pairment of hearing that led to severe functional deﬁcits. Both during
these studies and in the D3KO mice, serum T3 concentrations were
markedly elevated above normal, especially within a few hours of in-
jection. Interestingly, combined in situ hybridization studies showed
that Dio3 and Dio2 are expressed in different structures of the
cochlea, with different patterns, and that TRβmRNA expression over-
laps that of D3 but not of D2 [43].
The elegant studies summarized above provide ample evidence
that the expression of the deiodinases, thyroid hormone receptors,
and the T3 and T4 transporters is coordinated during the develop-
ment of the cochlea and that the speciﬁc disruption of either D2 or
D3 will result in an impairment of both the normal structural devel-
opment and the function of this organ. The next step in these studies
will be to deﬁne the endogenous signals that regulate the complex
and complementary modulation of local T3 production and degrada-
tion required for normal hearing.
2.3. Deiodinase-mediated effects during retinal development
Although D2 and D3 are expressed in the retinas of the chick,
Xenopus laevis, and Rana catesbeiana, D2 (and D1) are absent in the
mouse retina [44–46]. However, normal retinal development requires
thyroid hormone acting through TRβ2, which induces M opsin ex-
pression in cones [46,47]. Studies in Xenopus have suggested that
the asymmetric growth of the retina during metamorphosis is due
to D3 expression in the dorsal portions of this tissue [45]. D3 is also
found in the mouse retina but there does not appear to be any differ-
ence between its expression in the dorsal and ventral regions [46].
Surprisingly, studies in the D3KO mouse showed that, in the absence
of D3, 80% of cones were lost through apoptosis in the ﬁrst week of
neonatal life [46]. In contrast, the absence of D3 did not affect rod
photoreceptors. In subsequent studies, normal neonatal mice were
given graded doses of T3 to determine if exogenous T3 could over-
whelm the capacity of cone D3 to protect these cells. High doses of
T3 (leading to ~70- to 300-fold increases in circulating T3) caused
cone apoptosis. As was the case in T3-induced dysregulation of the
auditory system discussed above, ablation of TRβ2 expression elimi-
nated the apoptosis of the cones induced by excessive T3 thereby in-
dicating that this was a TR-dependent effect. Only extremely high
levels of T3 resulted in cone destruction and the sensitivity was limit-
ed to the ﬁrst week of neonatal life. Interestingly, in combined TRβ2/
D3KO mice, the cones appeared normal but did not express M opsin.
These studies are in an early phase and it is not yet clear what the
physiological ramiﬁcations might be for human retinal development.
However, it is apparent that D3 has a role in modulating the T3 con-
centration in cones, and that thyroid hormone-dependent destruction
of these cells may occur in its absence. Thus, both reduced and exces-
sive intra cellular T3 impairs normal retinal function, which illustrates
the critical role of deiodinases in the development of the visual
system.
2.4. Deiodinases in skeletal myogenesis
2.4.1. Thyroid hormone and muscle physiology
Skeletal muscle is a major peripheral tissue that accounts for ~40%
of the total body mass. It serves several purposes: movement,posture, stability, heat production, and cold tolerance. Furthermore,
it has a paramount role in energy balance, and is the primary tissue
of insulin-dependent glucose uptake and storage, and of regulation
of circulating and stored lipid ﬂux.
The overall contractile and metabolic feature of any single muscle
depends upon the properties of its ﬁber types and their proportions,
which are not ﬁxed entities but dynamic structures with an extraordi-
nary adaptive potential. Their phenotypic proﬁles are affected by such
factors as innervation, exercise training, mechanical loading/
unloading, hormones, and aging. To date, the most useful classiﬁca-
tions of muscle ﬁbers are based on their two major functional charac-
teristics: speed of contraction and the aerobic (oxidative)/anaerobic
(glycolytic) production of adenosine triphosphate. In general, con-
tractile speed is slowest in type I ﬁbers and fastest in type IIB ﬁbers.
Fast twitch ﬁbers (also known as type IIB or white ﬁbers) utilize an-
aerobic glycolysis, are low in mitochondria and myoglobin, rich in
glycogen, and are suited to short-term intense activity. Slow ﬁbers
(also known as type I or red ﬁbers) utilize aerobic metabolism, are
rich in mitochondria and myoglobin, and are suited to endurance ac-
tivity. Fast ﬁber type IIA is an intermediate ﬁber that combines fast
twitch capacity with aerobic fatigue, resistant metabolism, and inter-
mediate glycogen levels [48].
Skeletal muscle is one of the primary targets of thyroid hormones
[49], which have a profound inﬂuence on the relative concentrations
of MHC isoforms that ultimately affect the ﬁber type composition and
ﬁber type sizes. Moreover, by regulating the energy consumption and
heat production associated with activity, TH is the main determinant
of the resting metabolic rate of the muscle ﬁbers [48].
In general, hypothyroidism elicits fast-to-slow muscle ﬁber transi-
tions [49–51], while hyperthyroidism causes shifts in the reverse di-
rection. Accordingly, low levels of TH result in a decrease in muscle
mass and promote fast-to-slow transition in MHC isoform expression,
whereas high levels cause slow-to-fast shifts [52–54].
In addition to their impact on adult muscle ﬁber phenotypes, TH
plays an important role during muscle development and maturation.
Several muscle-speciﬁc genes (myogenes) are direct targets of TH.
TH–TR complexes have been demonstrated to regulate genes control-
ling metabolic homeostasis, such as GLUT4 [55], and energy expendi-
ture, such as UCP3 [56], and also to modulate the activity of a
number of Krebs cycle enzymes [57]. TH regulates the steady-state
levels of many different contractile protein mRNAs involved in ﬂuxes
of intracellular Ca2+, affecting the rate of contraction and relaxation
of muscle ﬁbers [58]. Moreover, the gene coding for the calcium
pump of the sarcoplasmic reticulum, SERCa2, is highly T3-responsive
and its regulatory region contains three thyroid hormone responsive
elements (TREs) [48].
Typical examples of T3-mediated control of speciﬁc myogenes are
changes in critical muscle-speciﬁc transcription factors (muscle regu-
latory factors, MRFs), including MyoD, the master regulator of
myogenesis and of the muscle regeneration process [49,50]. The
MyoD promoter contains a highly conserved TRE binding site that
can bind TR in vivo [41]. Furthermore, myogenin has been indicated
as a TH positively regulated gene [59]. The T3-mediated regulation
of the α and βMHC chains is more complex. T3 treatment stimulates
the expression of the MHCβ gene but decreases the expression of the
[59] MHCα gene. In hypothyroid muscles, V3 MHC predominates,
thus leading to the decreased velocity of muscle contraction. In con-
trast, in hyperthyroid rats, myosin is exclusively composed of V1,
which leads to an accelerated contraction due to the faster turnover
of the myosin moving along the thin ﬁlament [60].
Visser et al. examined the effects of L-thyroxine on the human
skeletal muscle transcriptome by investigating muscle gene expression
from 10 thyroidectomized patients before and 4 weeks after L-
thyroxine replacement [61]. They found that a large number of
TH-dependent genes involved in energy and fuel metabolism were
overrepresented among the up-regulated genes. Moreover, by
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showed that L-thyroxine therapy induced a large down-regulation of
the primary transcripts of the noncoding microRNA pair miR-206/
miR-133b, and concluded that TH plays complex role in the regulation
of cellular processes in human skeletal muscle by regulating a myriad
of genes, as well as microRNAs.
MicroRNA action is also critical for MHC expression as recently
demonstrated by van Rooij et al. [62]. They found that the cardiac-
speciﬁc miR-208 (encoded by an intron of the αMHC gene) is highly
sensitive to decreases in TH induced by PTU, which affect TH-
dependent transcriptional activity. The mRNA encoding TR Associated
Protein 1 (THRAP1) was among the strongest predicted targets of
miR-208 [63]. THRAP1 is a component of the TR-associated TRAP
complex and modulates TR activity by recruiting RNA polymerase II
and general initiation factors [64]. By repressing the expression of
the TR coregulator THRAP1, miR-208 can exert effects on TH-
dependent transcription [65]. Thus, miR-208 enhances βMHC expres-
sion and decreases αMHC expression, resulting in opposite regulation
of their expression by TH [65].
2.4.2. Deiodinases and muscle stem cells
“Satellite cells” are the most relevant population of muscle stem
cells; they are capable of self-renewal, and are able to differentiate
into myoblasts and to form new muscle ﬁbers. These small cells are
located beneath the basal lamina of the muscle ﬁber and are approx-
imately the same size as a muscle cell nucleus [66]. These cells are mi-
totically quiescent, but can be activated in response to muscle injury,
and are required for the formation of new myoﬁbers during postnatal
and adult life, and for the myoﬁber repair process [67,68]. Since mus-
cle ﬁbers are postmitotic, postnatal muscle growth and repair after
injury depend on the reservoir of satellite cells.
During embryonic muscle development, as well as during muscle
regeneration, satellite cells exit their normal quiescent state to enter
a deﬁned program that includes, in temporal sequence, proliferation,
differentiation, and fusion to form new myoﬁbers (Fig. 3). At
molecular level, early phases of this process are characterized by
upregulation of Pax7, Myf5, and MyoD expression. Following the pro-
liferative phase of myocyte precursor cells, myogenin and MRF4 are
upregulated so driving the terminal differentiation program [69],
which is completed with the withdrawal from the cell cycle, p21
upregulation, and speciﬁc MHC expression. Such a highly orchestrat-
ed process requires a hierarchy of several, time-dependent regulators.
Thyroid hormone has long been known to affect muscle develop-
ment and differentiation. More recent is the discovery of the pivotal
role of THmetabolism in muscle development. Although the presenceFig. 3. Thyroid hormone levels and myogenesis of satellite cells. In quiescence, satellite cells a
renewing. The TH signal is essential for the progression into terminal differentiation, while T
phase. The genes identiﬁed as T3 target during myogenesis are indicated.of D2 in skeletal muscle has long been recognized, its role has been
questioned given the very low speciﬁc activity and some muscle
tissue-speciﬁc confounding factors. These include the complex struc-
ture of muscle causing difﬁculties in extracting membrane-associated
proteins and the presence of a high concentration of metals that ulti-
mately lead to peroxidation and oxidation of DTT, essential for the
measurement of D2 activity in vitro [70]. Therefore, it is more appro-
priate to speciﬁcally quantify the labeled T3 by chromatographic
methods during D2 assays, thus avoiding an overestimation of D2 ac-
tivity due to an artifactual release of iodide not accompanied by T3
production [71].
Recently, using a novel, very sensitive D2-extraction protocol, we
identiﬁed D2 activity in mouse neonatal and adult muscles [41,72].
Interestingly, D2 is expressed in myoblast precursor cells and potent-
ly induced during differentiation. This was demonstrated in the myo-
genic cell line C2C12, as well as in the more physiologically relevant
primary culture of muscle precursor cells, termed “pp6” cells
(Fig. 4). D2 action, by increasing intracellular T3, promotes MyoD
gene expression and allows terminal differentiation. The critical role
played by D2 was demonstrated by the lack of proper differentiation
of pp6 cells derived from Dio2−/− mice [41].
By measuring enzymatic activity and mRNA levels, we found that
the expression of the T4-activating enzyme D2 in skeletal muscle dif-
fers depending on muscle ﬁber composition. Although D2 activity
was detectable in all hind limb muscles examined, it was higher in
the oxidative, type-I, slow twitch than in type II fast-twitch muscles
[72]. The role of D2 in skeletal muscle is underscored by the fact
that animals lacking D2 expression (Dio2−/−) show a mildly hypo-
thyroid pattern of muscle gene expression [41]. The consequences
of this in terms of muscle physiology and function are currently
under investigation.
Intracellular T3 concentration also has an impact on satellite cell
proliferation as demonstrated by the ﬁnding that activated muscle
precursor cells from Dio2−/− mice have a higher proliferation rate
than wild-type cells. Satellite cells from Dio2−/− mice have reduced
levels of MyoD, fail to fully differentiate and display a marked delay
in their regeneration program (Fig. 5), similar to satellite cells from
MyoD null mice [41]. This indicates that D2 activation lies upstream
of MyoD in the linear cascade of myogenesis in satellite cells, which
requires – for its normal sustained expression during regeneration
or development – both T3 from the plasma and that generated
by D2. Thus, the current hypothesis is that muscle-speciﬁc,
D2-mediated T4 activation is required for the proper expression of
MRFs, cell-cycle withdrawal, and subsequent fusion of myoblasts
into multinucleated myotubes (Fig. 3). In vivo, increased D2re a heterogeneous population of multipotent, undifferentiated cells capable of auto-
H downregulation is required to retain muscle progenitor cells (mpcs) in a proliferative
Fig. 4. Deiodinase expression proﬁle during myogenesis of satellite cells. D2 and D3 show opposite expression proﬁles during the satellite cell differentiation program. D3 expression is
sustained in the early phases of proliferation, but it declines sharply before differentiation. Conversely, D2 acts mainly in the differentiative stages, driving the TH-dependent up-
regulation of several myogenic proteins.
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levels of T3 are not sufﬁcient to sustain a full regeneration process.
Such a requirement has been elegantly demonstrated by injecting 125I-
T4 and 131I-T3 intowild type andDio2−/−mice, which allowed the eval-
uation of the relative contributions of plasma and D2-generated T3 in
regenerating muscles. The muscle production of 125I-T3 is doubled in
wild type, but not in Dio2−/−, mice after skeletal muscle injury [32].
How is D2 induced in differentiating myoblasts? We found that
the Dio2 gene is positively regulated by FoxO3a, a forkhead transcrip-
tion factor that integrates growth signals into several cellular func-
tions, including differentiation, metabolism, and survival [73,74]. In
skeletal muscle, FoxOs have been implicated in muscle differentiation
and, by inducing several autophagy-related genes, FoxO3 is the main
coordinator of muscle atrophy [75,76]. Acting in concert with Pax3/7
factors, FoxO3 binds to and regulates MyoD expression [77]. In
this scenario, it is relevant that the Dio2 gene is a direct target of
FoxO3a, and that Dio2 expression is signiﬁcantly reduced in FoxO3
null mice [41]. Moreover, we demonstrated that pp6 cells fromFig. 5. Impaired muscle regeneration in Dio2−/− mice. (A, B) Regeneration following CTX inju
by the high percentage of centrally located nuclei at day 15 following CTX injection. (C) D2
incorporation during muscle regeneration.
Figure modiﬁed from [41]FoxO3 null mice, which fail to completely differentiate due to the ab-
sence of MyoD, can be rescued by T3, thus overcoming their differen-
tiation defects. These data demonstrate that D2 lies between FoxO3
and MyoD expression in the intricate network that induces muscle
differentiation. In the myoblasts differentiation program, D3 and D2
expressions increase at different speciﬁc times (Dentice et al., manu-
script in preparation) so as to allow proliferation in advance of differ-
entiation (Fig. 4). Such a ﬁnely regulated proﬁle results in down
regulation of TH signaling in the proliferative phase of satellite cells
and a remarkable increase of intracellular TH during the differentia-
tion phase.
2.4.3. Deiodinases and muscle regeneration
Skeletal muscle possesses substantial regenerative capacity and
can undergo several rounds of repair following injury. In response
to wounding, quiescent satellite cells become activated, start to pro-
liferate, and their descendants, the mpc, undergo multiple rounds of
division before fusing into new ﬁbers. In several disease states,ry is signiﬁcantly delayed in Dio2−/−mice compared with wild type animals, as shown
depletion enhances proliferation of muscle progenitor cells as demonstrated by BrdU
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mass wasting and progressive muscle weakness, thereby resulting
in muscular dystrophy, muscle weakness, and metabolic disorders.
In Duchenne Muscular Dystrophy (DMD), a devastating inherited
neuromuscular disorder caused by the absence of a functional dys-
trophin, the dystrophic myoﬁbers need continuous cycles of muscle
regeneration, resulting in a constant need for satellite cell prolifera-
tion. However, with time, DMD regeneration cannot compensate for
the loss of muscle tissue, a process likely due to a progressive
decrease in the satellite cell reservoir. Consistent with this model,
several studies demonstrated that alterations in satellite cell prolif-
eration and/or differentiation have an impact onmuscular dystrophy
[78–81].
Several studies have examined the role of altered TH on the onset
of skeletal muscle dystrophy. They showed that alterations in TH
plasma levels have a profound impact on the phenotype of mdx
mice. McIntosh and Anderson demonstrated that hypothyroidism
worsens the phenotype of mdx mice by enhancing mpc proliferation
and delaying myotube formation [82]. McArdle and colleagues
found that induction of hypothyroidism exerts an initial positive ef-
fect on the dystrophic phenotype of mdxmice by preventing necrosis
in muscle and abolishing the characteristic elevation in serum Crea-
tine Kinase. This study was the ﬁrst to demonstrate that experimental
manipulation of TH levels altered the onset of necrosis in mdx mice
[83]. These ﬁndings were subsequently conﬁrmed in studies demon-
strating that antithyroid drugs reduce the rate of muscle degenera-
tion in avian muscular dystrophy. King and Entrikin showed that,
soon after hatching, induction of hypothyroidism improved muscle
function in dystrophic chickens [84]. An opposite effect was elicited
by T3 treatment, which accelerated precursor cell transition from
proliferation towards fusion in regenerating mdx and control mpc,
thereby limiting the number of myotubes generated during the repair
process [82,85].
Taken together, these data show that gross ﬂuctuations in TH sig-
niﬁcantly alter the muscle's response to dystrophy; hyperthyroidism
worsens the phenotype of mdx dystrophy by increasing the amount
of damage while hypothyroidism can, in the initial phase, ameliorate
the mdx dystrophic phenotype by enhancing the proliferative poten-
tial of mpc. Indeed, using the cardiotoxin-induced muscle injury par-
adigm, we demonstrated that D2 is signiﬁcantly up-regulated in the
later stages of muscle regeneration and that repair is signiﬁcantly del-
ayed in Dio2−/− compared with wild-type mice (Fig. 5). At day 15
after injury, muscle ﬁbers from Dio2−/− mice were still regenerating
as demonstrated by the centrally located nuclei, while wild type ani-
mals showed completed repair of the myoﬁbers; in fact, the number
of laterally located nuclei was nearly double that of Dio2−/− muscle
ﬁbers (Fig. 5). In agreement with the enhanced proliferation rate of
D2-deﬁcient myoblasts, the number of nuclei in regenerating tissues
of Dio2−/−mice was nearly twice that in muscles of similarly injured
wild type mice, which indicates that the overall mpc proliferation rate
was higher in vivo in the Dio2−/− environment than in controls. It is
intriguing that a very similar phenotype is observed in MyoD-null
mice in which myogenic stem cells are increased in number but im-
paired in their differentiation [82,86]. This correlation supports the
concept of a linear cascade in which Dio2 lies upstream of MyoD ex-
pression. These studies raise the possibility that tissue-speciﬁc modu-
lation of TH action could be used to prolong the period of myocyte
precursor cell proliferation prior to transplantation.
3. Role of deiodinases in different organs
The important role of local regulation of TH levels by the
deiodinases is by no means conﬁned to the tissues described above.
For example, D2-KO mice have elevated levels of both serum T4 and
TSH (with a normal serum T3), suggesting that there is a resistance
to the feedback mechanisms of T4 in the hypothalamus and/oranterior pituitary [87,88]. In brown adipose tissue (BAT), D2 provides
an essential local source of T3 to allow adaptive thermogenesis during
cold exposure. During cold exposure in D2-null mice, the animals sur-
vive only by compensatory shivering with consequent acute weight
loss [89]. In the lung, an increase in lung D2 is protective against
ventilator-induced lung injury, when an increase of immunoreactivi-
ty and D2 enzymatic activity was detected [90]. In the skeleton,
where hypothyroidism causes delayed bone formation and linear
growth retardation, important roles for Dio2 are emerging [91]. D2
activity was demonstrated in the perichondrium in the embryonic
chick growth plate [22], and in murine differentiated osteoblasts
[92]. Adult D2KO mice had brittle bones with impaired resistance to
fracture, indicating that maintenance of adult bone mineralization
and optimal bone strength requires local Dio2-mediated production
of T3 [92].
Thus, this brief list of additional examples indicates the critical
role of the deiodinases in conferring important local modulation of
thyroid hormone responsiveness in vivo to permit the fulﬁllment of
tissue-speciﬁc spatio-temporal requirements. One begins to sense
that this pathway for control of intracellular T3 concentrations during
development and regeneration may be the rule, not the exception.
4. Future directions
There is now compelling evidence that the control of TH action by
deiodinases signiﬁcantly affects the physiology of many organs and
tissues. The data available demonstrate that thyroid hormone levels
in the circulation do not faithfully reﬂect TH status in multiple cell
types. Although our knowledge is still primitive, the results obtained
to date raise the possibility of using deiodinases as therapeutic targets
to modify TH action in selected tissues.
A crucial question regarding the therapeutic potential of this po-
tent hormone is how to differentially modulate its action in a time-
and tissue-speciﬁc manner in order to avoid the deleterious effects
of excessive T3. In this respect, the modiﬁcation of TH deiodination
is a promising theoretical approach since it can increase or decrease
thyroid hormone signaling irrespective of thyroid hormone serum
concentrations. Thus, the spatio- and temporally-controlled regula-
tion of TH action via deiodinases would allow for the modulation of
the complex pattern of speciﬁc TH-sensitive gene expression in di-
verse developmental and disease states. Of course, a better under-
standing of thyroid hormone action at cellular level is a prerequisite
for the use of deiodinases for therapeutic purposes. In this scenario,
mouse models of tissue-speciﬁc knock outs and over-expression of
deiodinases will reveal how these enzymes impact TH signaling in se-
lected tissues and organs, and pave the way for their therapeutic
exploitation.
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